Previous studies of von Willebrand disease indicate that a deficiency of blood clotting Factor VIII/von Willebrand factor (FVIII/vWF) activity is responsible for the failure of platelets to participate fully in the initial stages of hemostasis. We have recently identified specific FVIII/vWF binding sites on platelets, suggesting that the interaction of these sites with FVIII/vWF may be functionally important in the development of platelet clumps. We have now studied how different ristocetin concentrations, various known platelet aggregation inhibitors, and the exposure of platelets to proteases affect the ability of platelets to bind FVIII/vWF and to form aggregates. Our results demonstrate a highly significant linear correlation between the degree of FVIII/vWF receptor binding and the extent of ristocetin-induced platelet aggregation. Because neither FVIII/vWF binding nor platelet aggregation occurs after platelets are exposed to low concentrations of proteases, the FVIII/vWF receptors must be in the platelet membrane. We conclude that the interaction between FVIII/vWVF protein and its receptors on the platelet membrane is an important mechanism by which platelet aggregation occurs during primary phase hemostasis.
Adhesion and aggregation of platelets to form hemostatic plugs at sites of vascular injury is a fundamental step of primary phase hemostasis (1, 2) . If such platelet interactions are impaired in humans, easy bruisability, mucocutaneous bleeding, and a prolonged bleeding time are usually observed (1) . These manifestations characterize the hereditary bleeding disorder, von Willebrand disease, in which the plasma Factor VIII/von Willebrand factor protein, or complex (FVIII/vWF), is deficient in amount or function (3) (4) (5) . In these patients there is a failure of platelets to stick and form clumps at the ends of transected vessels in skin wounds (6) . The bleeding disorder in patients with von Willebrand disease can be corrected by infusion of FVIII/vWF-containing cryoprecipitate (7) (8) (9) . FVIII/vWF is also an essential cofactor for human platelet aggregation in response to ristocetin, which is an observation that has been developed into an assay for vWF activity (10, 11) . The sum of such studies has led to the general conclusion that FVIII/vWF plays an important role in platelet plug formation during the initial stages of hemostasis.
Using a tadioligand receptor assay, we have recently identified specific binding sites for FVIII/vWF on washed human platelets (12) . The binding of FVIII/vWF to the platelet is ristocetin dependent and has a high affinity (Kd = 4.0-5.0 X 10-10 M). However, the correlation between the binding of the receptor and platelet aggregation has not been established. Purification of FVIII/vWF. FVIII/vWF was purified by polyethylene glycol precipitation and agarose gel (Bio-Gel A-lSm) chromatography as described (12) . The purity of the final product was confirmed by sodium dodecyl sulfate/urea gel electrophoresis (13) . This highly purified product was used throughout the study. '25Iodine-labeled FVIII/vWF (125I-FVIII/vWF) was prepared by the procedure reported earlier (12) . After iodination, no loss of vWF activity could be detected when compared to unlabeled FVIII/vWF in ristocetin-induced platelet aggregation analyses (14) .
Preparation of Washed Human Platelets and ProteaseTreated Platelets. Plasticware was used for drawing blood by a two-syringe technique from healthy volunteers and then for preparing fresh platelets by differential centrifugation. The platelets were washed five times with 50 mM Tris-HCI/0.15 M NaCl/0.1 M EDTA, pH 7.4 (12) , after which they were suspended in 3-4 ml'of 2.5 mM Tris-HCI/0.15 M NaCI/0.1% bovine serum albumin, pH 7.4 (Tris/saline/bovine serum albumin). If protease-treated platelets were to be prepared, then after the last wash the platelets were resuspended in 25 mM Tris-HCI/0.15 M NaCl, pH 7.4 (Tris/saline) to a concentration of ;109 platelets per ml. Three-milliliter aliquots of the platelet suspension were prepared, tnixed with a-chymotrypsin in final concentrations of 0, 10, 50, 100, or 200 Ag/ml, and left to' incubate for 15 min at 37°C with frequent stirring. The same conditions were used for trypsin-treated platelets except that each of two 3-ml aliquots of the platelet suspension was incubated with 0. 5 Fig. 2 shows a highly significant correlation (r = 0.96) between the extent of FVIII/vWF binding to platelets and the initial velocity of ristocetin-induced platelet aggregation when each was performed at the same ristocetin concentration (1 mg/ml). Hence, in the presence of ristocetin, the binding of FVIII/vWF to platelets apparently leads to platelet aggregation. Also in Fig. 2 it can be seen that platelet aggregation occurs only when greater than 10% of the total platelet receptors, ordinarily bound at 1 mg of ristocetin per ml, become occupied. DISCUSSION We recently reported on the identification and partial characterization of specific FVIII/vWF binding sites on human platelets (12) . At that time no attempt was made to correlate binding with a particular function in order to establish that such binding sites are truly receptors. To demonstrate that FVIII/ vWF binding to platelets is indeed responsible for ristocetininduced platelet aggregation, we used three approaches to establish such a relationship. Initially we showed that at a constant ristocetin concentration, the amount of bound FVIII/vWF is a linear function of the number of platelets present in the reaction mixture. Moreover, there is a high degree of correlation between the amount of FVIII/vWF bound and the initial ye- locity of ristocetin-induced platelet aggregation. We estimate that approximately 10% of the receptors observed at a ristocetin concentration of 1 mg/ml must be accessible for FVIII/vWF before platelet aggregation will occur. Although we observed that FVIII/vWF becomes fully bound to platelets in the presence of ristocetin, platelet aggregation was not initiated unless the suspension was stirred. Others have also observed that in the presence of an aggregating agent, platelets must be made to collide by mechanical means in order to clump (19, 20) . Our confirmation of this is important to our studies because it shows that the binding of FVIII/vWF to the platelet is not the result of platelet aggregation, but instead is a prerequisite for ristocetin-induced FVIII/vWF-dependent platelet aggregation.
The notion that the FVIII/vWF receptors must be localized to the platelet membrane is substantiated by our demonstration that FVIII/vWF binding is closely related to the degree of platelet exposure to trypsin and chymotrypsin. Our use of trypsin immobilized on agarose beads provides a convincing argument that the action of the protease was limited to the cell surface. The presence of FVIII/vWF receptors on the plasma membrane is also suggested from previous studies by other investigators, who showed that purified platelet membrane glycocalicin (21) or heterologous antibody to platelet membrane glycoprotein I (22) inhibits ristocetin-induced FVIII/vWFdependent platelet aggregation. The likelihood that the receptor is located on the platelet membrane is also suggested by ob-servations made by others on platelets from patients with the Bernard-Soulier syndrome (23) . Platelets from such patients are deficient in platelet membrane glycoprotein I and show little or no aggregation in response to ristocetin and added FVIII/vWF (23) . Finally, because the FVIII/vWF protein is very large, having a molecular weight of at least 1.1 X 106(24), it is unlikely that it traverses the platelet membrane to cause ristocetin-induced platelet aggregation.
Our next approach was to test the effects of known inhibitors of ristocetin-induced platelet aggregation on the binding of FVIII/vWF to the platelet. Although the inhibitory effects of these agents could occur by several possible mechanisms, we hypothesized that they might interfere with FVIII/vWF binding to the platelet. Our results clearly show that EDTA, EGTA, adenosine, and Evans blue inhibit FVIII/vWF binding to platelets and that there is high degree of correlation between the suppression of binding and the inhibition of ristocetininduced platelet aggregation. We could not determine whether these agents interact with the FVIII/vWF protein or, instead, with the platelet recpptor that is either formed or made available in the presence of ristocetin.
In conclusion, our results establish the functional significance of FVIII/vWF specific binding sites on human platelets; hence, the criterion of function is now fulfilled for recognizing these specific binding sites as receptors. Clearly, binding of FVIII/ vWF to these receptors is directly correlated with ristocetininduced platelet aggregation. Although the in vivo counterpart of ristocetin is still upknown, the dependency on ristocetin for either forming part of the platelet membrane receptor for FVIII/vWF or, at least, making such a receptor accessible suggests that an in mvo analogue to ristocetin might exist. 
